A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma

Hum Gene Ther. 2000 Feb 10;11(3):487-503. doi: 10.1089/10430340050015950.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Adenoviridae / genetics*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Female
  • Ganciclovir / administration & dosage
  • Ganciclovir / therapeutic use*
  • Genetic Therapy*
  • Genetic Vectors
  • Herpesvirus 1, Human / enzymology
  • Herpesvirus 1, Human / genetics*
  • Humans
  • Male
  • Melanoma / therapy*
  • Skin Neoplasms / therapy*
  • Thymidine Kinase / genetics*

Substances

  • Antiviral Agents
  • Thymidine Kinase
  • Ganciclovir